Publications

1. Nunn, M. A., A. Sharma, G. C. Paesen, S. Adamson, O. Lissina, A. C. Willis, and P. A. Nuttall. (2005). Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol 174:2084-2091.

2. Hepburn, N. J., A. S. Williams, M. A. Nunn, J. C. Chamberlain-Banoub, J. Hamer, B. P. Morgan, and C. L. Harris. (2007). In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 282:8292-8299.

3. Roversi P., O. Lissina, S. Johnson, N. Ahmat, G. C. Paesen, K. Ploss, W. Boland, M. A. Nunn, and S. M. Lea. (2007). The structure of OMCI, a novel lipocalin inhibitor of the complement system. Journal of molecular biology 369:784-793.

4. Mans BJ, Ribeiro JM. Function, mechanism and evolution of the moubatin-clade of soft tick lipocalins. Insect Biochem Mol Biol. 2008 Sep;38(9):841-52.

5. Soltys, J., L. L. Kusner, A. Young, C. Richmonds, D. Hatala, B. Gong, V. Shanmugavel, and H. J. Kaminski. (2009). Novel complement inhibitor limits severity of experimentally myasthenia gravis. Annals of neurology 65:67-75.

6. Fredslund, F., N. S. Laursen, P. Roversi, L. Jenner, C. L. Oliveira, J. S. Pedersen, M. A. Nunn, S. M. Lea, R. Discipio, L. Sottrup-Jensen, and G. R. Andersen. (2008). Structure of and influence of a tick complement inhibitor on human complement component 5. Nature immunology 9:753-760.

7. Halstead, S. K., P. D. Humphreys, F. M. Zitman, J. Hamer, J. J. Plomp, and H. J. Willison. (2008). C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst 13:228-235.

8. Kaminski, H. J. (2007). Restoring balance at the neuromuscular junction. Neurology 69:629-630. (Editorial)

9. Barratt-Due A, Thorgersen EB, Lindstad JK, Pharo A, Lissina O, Lambris JD, Nunn MA, Mollnes TE. 2011. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J.Immunol. (2011 Nov) 1;187(9):4913-9. Epub 2011 Sep 30.

10. Garcia C.C., Weston-Davies W, Russo RC, Tavares LP, Rachid MA, Alves-Filho JC, Machado AV, Ryffel B, Nunn MA, Teixeira MM (2013). Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury. PLoS One 8(5): e64443.

11. Roversi P, Ryffel B, Togbe D, Maillet I, Teixeira M, Ahmat N, Paesen GC, Lissina O, Boland W, Ploss K, Caesar JJ, Leonhartsberger S, Lea SM, Nunn MA. (2013). Bifunctional lio]pocalin ameliorates murine immune complex –induced lung injury. J Biol Chem 288(26): 18789 -802.

12. Barratt-Due A, Thorgersen EB, Egge K, Pischke S, Sokolov A, Hellerud BC, Lindstad JK, Pharo A, Bongoni AK, Rieben R, Nunn M, Scott H, Mollnes TE. (2013). Combined inhibition of complement C5 and CD14 markedly attenuates inflammation, thrombogenicity and haemodynamic changes in porcine sepsis. J Immunol 191 (2): 812-27.

13. Fluiter K1, Opperhuizen AL, Morgan BP, Baas F, Ramaglia V. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol. 2014 Mar 1;192(5):2339-48.

14. Westwood J-P, Weston-Davies WH, Hillmen P, Richards SJ, Mackie IJ, Machin SJ and Prudo R. Coversin, a Small Protein Complement Inhibitor, is a Potential Novel Anti-thrombotic Agent. British Journal of Haematology, May 2014, 165, (Suppl.) 3

15. Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger Ø, Nilsson PH, Nunn MA, Denk S, Gaus W, Espevik T, Mollnes TE. Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and improves Morbidity and Survival in Polymicrobial Sepsis in Mice. J Immunol. 2014 Jun 1;192(11):5324-31.

16. Romay-Penabad Z, Carrera Marin AL, Willis R, Weston-Davies W, Machin S, Cohen H, Brasier A, Gonzalez EB. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct;23(12):1324-6.

17. Blom AM, Volokhina EB, Fransson V, Strömberg P, Berghard L, Viktorelius M, Mollnes TE, López-Trascasa M, van den Heuvel LP, Goodship TH, Marchbank KJ, Okroj M. A novel method for direct measurement of complement convertases activity in human serum. Clin Exp Immunol. 2014 Oct;178(1):142-53.

18. Egge KH, Thorgersen EB, Pischke SE, Lindstad JK, Pharo A, Bongoni AK, Rieben R, Nunn MA, Barratt-Due A, Mollnes TE. Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14.Immunobiology. 2015 Aug;220(8):999-1005.

19. Berends ET, Mohan S, Miellet WR, Ruyken M, Rooijakkers SH. Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum. Mol Immunol. 2015 Jun;65(2):328-35.

20. Ueda Y, Osato M, Weston-Davies W, Nunn M, Hayashi S, Nishimura J, Kanakura Y. Coversin Blocked in vitro Hemolysis in an Eculizumab-Resistant PNH Patient with the C5 Polymorphism (c.2654G>A). ASH 2015.

21. Langemeijer S, Nishimura J, Weston-Davies W, Nunn M, Kanakura Y, Mackie I, Muus P. C5 polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria and no Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin.  ASH 2015.

22. Langemeijer S, Weston-Davies W, Nunn M, Nishimura J, Kanakura Y, Blijlevens N, Nijziel M, Muus P. 12 weeks safety and efficacy results of the novel C5 inhibitor Coversin in PNH with resistance to eculizumab due to complement C5 polymorphism. EHA 2016.

23. Nunn M, Skerra A. Therapeutic Development of Complement C5 inhibitor CoversinTM with Extended Half-life via PASylation®, 58th Annual American Society of Hematology. ASH 2016

Additional
1. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, Inazawa J, Kinoshita T, Kanakura Y. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 Feb 13;370(7):632-9.